ArticleMovement disorders : official journal of the Movement Disorder Society2026
Stimulation and Medication Effects on Subthalamic Nucleus Beta-Band Power in Parkinson's Disease: Implications for Adaptive Deep Brain Stimulation.
Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Place of Adaptive Deep Brain Stimulation in Parkinson's Disease: Spatial before Temporal Optimization.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Local field potential biomarkers for adaptive deep brain stimulation in Parkinson's disease: A scoping review.Surgical neurology international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAdaptive deep brain stimulation (aDBS) using subthalamic nucleus (STN) beta-band oscillations as a biomarker for the akinetic-rigid symptoms of Parkinson's disease has been proposed to improve the efficacy of stimulation and decrease adverse effects. However, most studies validating STN beta oscillations as a biomarker used perioperative, off medication, and OFF stimulation conditions, limiting their potential relevance to real-world aDBS deployment.
objectiveWe evaluated how stimulation and dopaminergic medication affect beta-range STN oscillatory activity and its ability to predict the hypokinetic parkinsonian state.
methodsIn six patients with Parkinson's disease who experienced residual levodopa-related motor fluctuations despite standard-of-care DBS, we studied medication cycle-induced fluctuations of peak STN beta oscillation power during active DBS. We evaluated the magnitude of beta oscillation fluctuations, the frequency of peak beta activity, and the ability to predict the off medication state. Neural signals were collected in the clinic during a medication challenge and at home during naturalistic medication cycles.
resultsMedication-induced beta oscillation fluctuations were smaller in the presence of therapeutic DBS compared with when the stimulator was off (P = 0.008). Therapeutic stimulation also decreased the frequency of peak beta activity (P < 0.001). As a result, the beta frequencies with the highest power in the OFF stimulation/off medication state were less accurate than other beta-range bands at predicting the patient's off medication state during active stimulation (P = 0.02).
conclusionsThe spectral characteristics of STN beta oscillations and their performance as a biomarker in aDBS for Parkinson's disease are influenced by the stimulation and medication conditions in which it is implemented. © 2026 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.